Investment Thesis
NewAmsterdam Pharma exhibits catastrophic operational deterioration with 50.6% YoY revenue collapse to $22.5M and a -$225.7M operating loss generating -1002.9% operating margin. The company is burning $148M annually in negative free cash flow, making current operations fundamentally unsustainable despite a $490M cash cushion. The magnitude of losses relative to revenue indicates severe business model dysfunction requiring dramatic operational restructuring or successful pipeline catalysts to justify investment.
Strengths
- Strong cash position of $490M provides 3-4 year runway even at current burn rate
- Minimal debt exposure with 0.00x debt-to-equity ratio and $85.9M total liabilities
- Excellent liquidity metrics with 7.88x current and quick ratios provide financial flexibility
Risks
- Revenue collapse of 50.6% YoY to $22.5M indicates severe product, market, or competitive challenges
- Operating loss of $225.7M on minimal revenue demonstrates fundamental business model breakdown
- Negative operating cash flow of -$147.8M shows unsustainable cash burn that will deplete reserves despite strong balance sheet
Key Metrics to Watch
- Revenue stabilization and pathway to positive growth
- Operating cash flow trends and rate of cash reserve depletion
- Pipeline clinical trial results and regulatory approvals driving potential business recovery
Financial Metrics
Revenue
22.5M
Net Income
-203.8M
EPS (Diluted)
$-1.72
Free Cash Flow
-148.0M
Total Assets
769.3M
Cash
490.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,002.9%
Net Margin
-905.7%
ROE
-29.8%
ROA
-26.5%
FCF Margin
-657.8%
Balance Sheet & Liquidity
Current Ratio
7.88x
Quick Ratio
7.88x
Debt/Equity
0.00x
Debt/Assets
11.2%
Interest Coverage
-786.35x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-13T00:48:22.966738 |
Data as of: 2025-12-31 |
Powered by Claude AI